WM Artphoto, Maria Westling

We are a research-based company in the cancer diagnostic field. We have developed ColoNode®- a biomarker test for accurate detection and characterization, of cancer cells in lymph nodes of colorectal cancer patients.

Colorectal cancer is the third most common cancer worldwide. Half of all patients die from the disease, despite available treatments. Additional chemotherapy following surgery can reduce the risk of recurrent cancer, but the currently used methods for selecting patients for different treatment options are inaccurate and ineffective. This results in both over- and undertreatment with unnecessary human suffering and high costs.

HiloProbe is developing a highly accurate test to identify each patient’s need of treatment after surgery for colorectal cancer. Examination of lymph node tissue with ColoNode® offers clinicians a rapid, objective and accurate routine for detection of cancer cells and determination of their aggressiveness.

We have shown ColoNode® to be a quick, objective and reliable method for evaluation of all retrieved lymph nodes from the resected specimen. We therefore believe that the biomarker test ColoNode® will replace light microscopy of lymph nodes for diagnosis and prognostication of colorectal cancer in the future.

Northern Light Capital investerar i HiloProbe

HiloProbe tar in kapital – siktar mot en internationell marknad HiloProbe AB med säte i Umeå utvecklar nya diagnostiska metoder för kolorektalcancer, dvs. cancer i tjock- och ändtarm. Detta är den tredje vanligaste cancertypen globalt och ca 50% av alla som får...

Funded by